Chronic lymphocytic leukaemia+1
RecruitingStudy on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:ObinutuzumabPirtobrutinib+1
France- Participants:18–64 years · 65+ years
- Substances:Obinutuzumab
- Sponsor:University Of Cologne






